



pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion

Vienna, Austria, and Mölndal, Västra Götaland, Sweden, February 1, 2024 –pharmaand GmbH (pharma&) and GHN Pharma Nordic AB are pleased to announce the renewal and expansion of their partnership. This marks a significant milestone in a collaboration that began in 2021, further cementing the relationship and shared vision between the two companies. In 2021, GHN Pharma Nordic and pharma& embarked on a transformative journey with a 5-year contract that included Pegasys® (peginterferon alfa-2a).

The success of this partnership has paved the way for the recent agreement signed on December 22, 2023, extending the collaboration for an additional five years starting January 1, 2024. This new agreement introduces two central medicines to the partnership: Farydak® (panobinostat) in hematology and Rubraca® (rucaparib) in oncology. These additions are poised to significantly bolster GHN Pharma Nordic's presence in these strategically important areas, demonstrating the potential benefit to eligible patients. GHN Pharma Nordic has established a strong presence in the Nordic pharmaceutical market. The Company has successfully launched a diverse range of medicines through rapid growth and an innovative approach.

“Our extended partnership with pharma& is not just a business agreement; it's a fusion of shared goals and visions,” said Tina Madsen Sandström, CEO of GHN Pharma Nordic. “The addition of Farydak and Rubraca to our portfolio is a significant step in our mission to provide comprehensive healthcare solutions. We are excited about this new chapter and the opportunities it brings.”

“The strengthened collaboration with GHN Pharma Nordic reflects the joint commitment to provide access to essential healthcare solutions,” said Elmar Zagler, Founder and Managing Director of pharma&. “We are proud to continue our journey with a partner who shares our dedication to making a potential difference in the lives of eligible patients.”

GHN Pharma Nordic looks forward to providing availability updates for Rubraca and Farydak in the future.

About pharma&

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines through an agile and fully integrated business model, guaranteeing the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Over the past five years, pharma& has acquired and integrated 12 medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution and services to patients.

About GHN Pharma Nordic AB

Since its establishment in late 2021, GHN Pharma Nordic AB has launched prescription pharmaceuticals in urology, psychiatry, and hematology, medical devices in dermatology and hematology, and a full range of products in rare metabolic diseases. With operations across all Nordic countries, GHN Pharma Nordic's expansion for 2024 includes plans to introduce new pharmaceuticals in dermatology, allergology, and ophthalmology.

To the extent that statements contained in this press release are not descriptions of historical facts regarding pharma&, they are forward-looking statements reflecting management's current beliefs and expectations. Examples of forward-looking statements contained in this press release include, among others, statements regarding our future financial and operating performance and business plans or prospects. Such forward-looking statements involve substantial risks and uncertainties that could cause pharma&'s actual results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in pharmaceutical manufacturing. pharma& undertakes no obligation to update or revise any forward-looking statements.

#

GHN Pharma Nordic Contact:

Infonordic@ghnpharma.com

pharma& Media Contact:

media@pharmaand.com